title: [Insulin detemir(NN-304)].
abstract: A line of evidences has demonstrated that a normalization of blood glucose can prevent or delay diabetic complications. To normalize blood glucose in diabetic patients who require insulin treatment, a tailoring the time-action profile of injected insulin is needed. B29Lys-myristoyl. des-B30 human insulin(NN-304), which metabolic action is prolonged by association of the fatty acid residue to albumin in the blood and peripheral tissues, belongs to a new class of soluble long-acting insulin analogs. The aim of clinical development of NN-304 is to reduce the disadvantages of currently available long-acting insulin formulations. NN-304 might offer advantages in clinical use such as reproducing physiological basal insulin action derived from a flatter time-action profile.
authors.affiliation: Diabetes & Endocrinology Division, Kawasaki Medical School.
authors.forename: K
authors.initials: K
authors.lastname: Kaku
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D002352:Carrier Proteins / Q000493:pharmacokinetics / Q000494:pharmacology; D017321:Clinical Trials, Phase I as Topic; D003692:Delayed-Action Preparations; D006801:Humans; D007004:Hypoglycemic Agents; D007328:Insulin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D000069057:Insulin Detemir; D049528:Insulin, Long-Acting; D008969:Molecular Sequence Data
chemical_list: D002352:Carrier Proteins; D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069057:Insulin Detemir